-
Je něco špatně v tomto záznamu ?
Lipid and brain volumetric measures in multiple sclerosis patients: findings from a large observational study
B. Lorincz, M. Vrablik, R. Murali, EK. Havrdova, D. Horakova, J. Krasensky, M. Vaneckova, T. Uher
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, pozorovací studie
Grantová podpora
64165
RVO VFN
- MeSH
- cholesterol krev MeSH
- dospělí MeSH
- HDL-cholesterol * krev MeSH
- kohortové studie MeSH
- LDL-cholesterol krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- magnetická rezonanční tomografie * MeSH
- mozek * diagnostické zobrazování patologie MeSH
- průřezové studie MeSH
- roztroušená skleróza * diagnostické zobrazování krev patologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
OBJECTIVES: This study aimed to investigate relationships between cholesterol profile, brain volumetric MRI, and clinical measures in a large observational cohort of multiple sclerosis (MS) patients. MATERIALS AND METHODS: We included 1.505 patients with 4.966 time points including complete lipid, clinical, and imaging data. The time among lipid, brain MRI and clinical measures was under 90 days. Cross-sectional statistical analysis at baseline was performed using an adjusted linear regression and analysis of longitudinal lipid and MRI measures data was performed using adjusted linear mixed models. RESULTS: We found associations between higher high-density lipoprotein cholesterol (HDL-C) and lower brain parenchymal fraction (BPF) at cross-sectional analysis at baseline (B = -0.43, CI 95%: -0.73, -0.12, p = 0.005), as well as in longitudinal analysis over follow-up (B = -0.32 ± 0.072, χ2 = 36.6; p = < 0.001). Higher HDL-C was also associated with higher T2-lesion volume in longitudinal analysis (B = 0.11 ± 0.023; χ2 = 23.04; p = < 0.001). We observed a weak negative association between low-density lipoprotein cholesterol (LDL-C) levels and BPF at baseline (B = -0.26, CI 95%: -0.4, -0.11, p = < 0.001) as well as in longitudinal analysis (B = -0.06 ± 0.03, χ2 = 4.46; p = 0.03). T2-LV did not show an association with LDL-C. We did not find any association between lipid measures and disability. The effect of lipid levels on MRI measures and disability was minimal (Cohen f2 < 0.02). CONCLUSIONS: Our results contradict the previously described exclusively positive effect of HDL-C on brain atrophy in patients with MS. Higher LDL-C was weakly associated with higher brain atrophy but not with higher lesion burden.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25003195
- 003
- CZ-PrNML
- 005
- 20250206104110.0
- 007
- ta
- 008
- 250121s2024 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13760-024-02676-w $2 doi
- 035 __
- $a (PubMed)39455532
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Lorincz, Balazs $u Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 245 10
- $a Lipid and brain volumetric measures in multiple sclerosis patients: findings from a large observational study / $c B. Lorincz, M. Vrablik, R. Murali, EK. Havrdova, D. Horakova, J. Krasensky, M. Vaneckova, T. Uher
- 520 9_
- $a OBJECTIVES: This study aimed to investigate relationships between cholesterol profile, brain volumetric MRI, and clinical measures in a large observational cohort of multiple sclerosis (MS) patients. MATERIALS AND METHODS: We included 1.505 patients with 4.966 time points including complete lipid, clinical, and imaging data. The time among lipid, brain MRI and clinical measures was under 90 days. Cross-sectional statistical analysis at baseline was performed using an adjusted linear regression and analysis of longitudinal lipid and MRI measures data was performed using adjusted linear mixed models. RESULTS: We found associations between higher high-density lipoprotein cholesterol (HDL-C) and lower brain parenchymal fraction (BPF) at cross-sectional analysis at baseline (B = -0.43, CI 95%: -0.73, -0.12, p = 0.005), as well as in longitudinal analysis over follow-up (B = -0.32 ± 0.072, χ2 = 36.6; p = < 0.001). Higher HDL-C was also associated with higher T2-lesion volume in longitudinal analysis (B = 0.11 ± 0.023; χ2 = 23.04; p = < 0.001). We observed a weak negative association between low-density lipoprotein cholesterol (LDL-C) levels and BPF at baseline (B = -0.26, CI 95%: -0.4, -0.11, p = < 0.001) as well as in longitudinal analysis (B = -0.06 ± 0.03, χ2 = 4.46; p = 0.03). T2-LV did not show an association with LDL-C. We did not find any association between lipid measures and disability. The effect of lipid levels on MRI measures and disability was minimal (Cohen f2 < 0.02). CONCLUSIONS: Our results contradict the previously described exclusively positive effect of HDL-C on brain atrophy in patients with MS. Higher LDL-C was weakly associated with higher brain atrophy but not with higher lesion burden.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a roztroušená skleróza $x diagnostické zobrazování $x krev $x patologie $7 D009103
- 650 12
- $a magnetická rezonanční tomografie $7 D008279
- 650 12
- $a mozek $x diagnostické zobrazování $x patologie $7 D001921
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a HDL-cholesterol $x krev $7 D008076
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a cholesterol $x krev $7 D002784
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Vrablik, Michal $u Third Department of Internal Medicine, Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Murali, Ramanathan $u Department of Pharmaceutical Sciences and Neurology, University at Buffalo, State University of New York, Buffalo, NY, USA
- 700 1_
- $a Havrdova, Eva Kubala $u Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Horakova, Dana $u Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Krasensky, Jan $u Department of Radiology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Vaneckova, Manuela $u Department of Radiology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Uher, Tomas $u Department of Neurology, Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic. tomas.uher@vfn.cz $1 https://orcid.org/0000000331609022 $7 xx0189534
- 773 0_
- $w MED00000090 $t Acta neurologica Belgica $x 2240-2993 $g Roč. 124, č. 6 (2024), s. 1981-1988
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39455532 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206104106 $b ABA008
- 999 __
- $a ok $b bmc $g 2263128 $s 1239202
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 124 $c 6 $d 1981-1988 $e 20241025 $i 2240-2993 $m Acta neurologica Belgica $n Acta Neurol Belg $x MED00000090
- GRA __
- $a 64165 $p RVO VFN
- LZP __
- $a Pubmed-20250121